Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced non-
small cell lung carcinoma (NSCLC). Building off of this, it has been hypothesized that the …

Genetic testing is crucial for precision cancer medicine. However, detecting multiple same-
site insertions or deletions (indels) is challenging. Here, we introduce CoHIT (Cas12a-based …

Purpose: Patient-tailored minimal residual disease (MRD) monitoring based on circulating
tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection of …

Lung cancer is a highly prevalent malignancy worldwide and the primary cause of mortality.
The absence of systematic and standardized diagnostic approaches for identifying potential …

In an era of expanding perioperative approaches for resectable non–small-cell lung cancer,
new data demonstrate that dual neoadjuvant immunotherapy targeting PD-1 and LAG-3 is …

Lung cancer is a widely occurring and deadly malignancy, with high prevalence rates in
China and across the globe. Specifically, non-small cell lung cancer (NSCLC) represents …

Lung cancer currently represents a leading cause of cancer death. Substantial progress
achieved in the medical therapy of lung cancer during the last decade has been associated …

Melanoma is a dangerous form of skin cancer that results in the demise of patients at the
developed stage. Researchers have attempted to develop automated systems for the timely …

Circulating tumor DNA (ctDNA) in the bloodstream can be used to reliably identify a minimal
residual disease (MRD). ctDNA-MRD has demonstrated clinical values as a predictive and …

Objective The study objective was to evaluate the impact of monitoring circulating tumor
DNA on the detection and management of recurrence in patients with resected early-stage …